Literature DB >> 11375370

Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study.

T J Orchard1, K Y Forrest, L H Kuller, D J Becker.   

Abstract

OBJECTIVE: Subjects with type 1 diabetes are at high risk for many long-term complications, including early mortality and coronary artery disease (CAD). Few data are available on which to base goal levels for two major risk factors, namely blood pressure and lipid/lipoproteins. The objective of this study was to determine at which levels of LDL and HDL cholesterol, triglycerides, and blood pressure the relative risks of type 1 diabetic complications increase significantly. RESEARCH DESIGN AND METHODS: Observational prospective study of 589 patients with childhood-onset type 1 diabetes (<17 years) aged > or =18 years at baseline; 10-year incidence of mortality, CAD, lower-extremity arterial disease, proliferative retinopathy, distal symmetric polyneuropathy, and overt nephropathy. Relative risks were determined using traditional groupings of blood pressure and lipid/lipoproteins, measured at baseline, using the lowest groupings (<100 mg/dl [2.6 mmol/l] LDL cholesterol, <45 mg/dl [1.1 mmol/l] HDL cholesterol, <100 mg/dl [1.1 mmol/l] triglycerides, <110 mmHg systolic blood pressure, and <80 mmHg diastolic blood pressure) as reference. Adjustments for age, sex, and glycemic control were examined.
RESULTS: Driven mainly by strong relationships (RR range 1.8-12.1) with mortality, CAD, and overt nephropathy, suggested goal levels are as follows: LDL cholesterol <100 mg/dl (2.6 mmol/l), HDL cholesterol >45 mg/dl (1.1 mmol/l), triglycerides <150 mg/dl (1.7 mmol/l), systolic blood pressure <120 mmHg, and diastolic blood pressure <80 mmHG: Age, sex, and glycemic control had little influence on these goals.
CONCLUSIONS: Although observational in nature, these data strongly support the case for vigorous control of lipid levels and blood pressure in patients with type 1 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375370     DOI: 10.2337/diacare.24.6.1053

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  44 in total

Review 1.  Standards of medical care in diabetes--2012.

Authors: 
Journal:  Diabetes Care       Date:  2012-01       Impact factor: 19.112

Review 2.  Cardiovascular disease risk in young people with type 1 diabetes.

Authors:  Janet K Snell-Bergeon; Kristen Nadeau
Journal:  J Cardiovasc Transl Res       Date:  2012-04-12       Impact factor: 4.132

3.  Standards of medical care in diabetes--2011.

Authors: 
Journal:  Diabetes Care       Date:  2011-01       Impact factor: 19.112

4.  JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice.

Authors: 
Journal:  Heart       Date:  2005-12       Impact factor: 5.994

5.  Standards of medical care in diabetes--2009.

Authors: 
Journal:  Diabetes Care       Date:  2009-01       Impact factor: 19.112

6.  Standards of medical care in diabetes--2010.

Authors: 
Journal:  Diabetes Care       Date:  2010-01       Impact factor: 19.112

Review 7.  [Diagnosis, treatment and monitoring of diabetic eye control].

Authors:  Stephan Radda; Matthias Bolz; Stefan Egger; Vanessa Gasser-Steiner; Martina Kralinger; Stefan Mennel; Christoph Scholda; Ulrike Stolba; Andreas Wedrich; Katharina Krepler
Journal:  Wien Klin Wochenschr       Date:  2016-04       Impact factor: 1.704

8.  [Diagnosis, therapy and follow up of diabetic eye disease].

Authors:  Michael Stur; Stefan Egger; Anton Haas; Gerhard Kieselbach; Stefan Mennel; Reinhard Michl; Michael Roden; Ulrike Stolba; Andreas Wedrich
Journal:  Wien Klin Wochenschr       Date:  2012-12       Impact factor: 1.704

Review 9.  Mitigating micro-and macro-vascular complications of diabetes beginning in adolescence.

Authors:  Daniel J Moore; Justin M Gregory; Yaa A Kumah-Crystal; Jill H Simmons
Journal:  Vasc Health Risk Manag       Date:  2009-11-23

10.  Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).

Authors: 
Journal:  BMC Pediatr       Date:  2009-12-17       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.